For You
News & Perspective
Drugs & Diseases
CME & Education
Academy
Video
Decision Point
Edition: English

Medscape

English
Deutsch
Español
Français
Português
UKNew

Univadis

Sign Up It's Free!
English Edition

Medscape

Univadis

    X
    Univadis from Medscape

    No Results

      For You News & Perspective Drugs & Diseases CME & Education Academy Video Decision Point
      Drugs & Diseases

      oxybutynin topical (Rx)

      Brand and Other Names:Gelnique
      • Print

      Dosing & Uses

      AdultPediatric

      Dosage Forms & Strengths

      topical gel

      • 10%; supplied as 100mg/1g unit (1.14mL) sachet

      Overactive Bladder

      Indicated for treatment of overactive bladder with symptoms of urge incontinence, frequency, and urgency

      Gel sachet (10%): Apply 100 mg (content of 1 sachet 10%) qDay

      Administration

      For topical application only; should not be ingested

      Apply to dry, intact skin on abdomen, upper arms/shoulders, or thigh

      Wash hands immediately after application; cover application site with clothing after gel has dried if direct skin-to-skin contact is anticipated

      Avoid showering for 1 hr following application

      Rotate application sites, avoid same site on consecutive days

      Safety and efficacy not established

      Next:

      Interactions

      Interaction Checker

      and oxybutynin topical

      No Results

         activity indicator 
        No Interactions Found
        Interactions Found

        Contraindicated

          Serious - Use Alternative

            Significant - Monitor Closely

              Minor

                All Interactions Sort By:
                 activity indicator 

                Contraindicated (0)

                  Serious - Use Alternative (3)

                  • lonafarnib

                    oxybutynin topical will increase the level or effect of lonafarnib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown.

                  • pramlintide

                    pramlintide, oxybutynin topical. Either increases effects of the other by pharmacodynamic synergism. Contraindicated. Synergistic inhibition of GI motility.

                  • secretin

                    oxybutynin topical decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.

                  Monitor Closely (100)

                  • abobotulinumtoxinA

                    abobotulinumtoxinA increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.

                  • aclidinium

                    oxybutynin topical and aclidinium both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • amantadine

                    oxybutynin topical, amantadine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Potential for increased anticholinergic adverse effects.

                  • amitriptyline

                    oxybutynin topical and amitriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • amoxapine

                    oxybutynin topical and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • anticholinergic/sedative combos

                    anticholinergic/sedative combos and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • aripiprazole

                    oxybutynin topical decreases levels of aripiprazole by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of aripiprazole by pharmacodynamic antagonism. Use Caution/Monitor.

                    aripiprazole increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • atracurium

                    atracurium and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • atropine

                    atropine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • atropine IV/IM

                    atropine IV/IM and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • avapritinib

                    oxybutynin topical will increase the level or effect of avapritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

                  • axitinib

                    oxybutynin topical increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

                  • belladonna alkaloids

                    belladonna alkaloids and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • belladonna and opium

                    belladonna and opium and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • benperidol

                    oxybutynin topical decreases levels of benperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of benperidol by pharmacodynamic antagonism. Use Caution/Monitor.

                    benperidol increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • benztropine

                    benztropine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor. Additive anticholinergic adverse effects may be seen with concurrent use.

                  • bethanechol

                    bethanechol increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • carbachol

                    carbachol increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • cevimeline

                    cevimeline increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • chlorpromazine

                    oxybutynin topical decreases levels of chlorpromazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of chlorpromazine by pharmacodynamic antagonism. Use Caution/Monitor.

                    chlorpromazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • cisatracurium

                    cisatracurium and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • clomipramine

                    oxybutynin topical and clomipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • clozapine

                    oxybutynin topical decreases levels of clozapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of clozapine by pharmacodynamic antagonism. Use Caution/Monitor.

                    clozapine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • cyclizine

                    cyclizine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • cyclobenzaprine

                    cyclobenzaprine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • darifenacin

                    darifenacin and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • desipramine

                    oxybutynin topical and desipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • dicyclomine

                    dicyclomine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • diphenhydramine

                    diphenhydramine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • donepezil

                    donepezil increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • donepezil transdermal

                    donepezil transdermal, oxybutynin topical. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.

                  • dosulepin

                    oxybutynin topical and dosulepin both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • doxepin

                    oxybutynin topical and doxepin both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • droperidol

                    oxybutynin topical decreases levels of droperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of droperidol by pharmacodynamic antagonism. Use Caution/Monitor.

                    droperidol increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • echothiophate iodide

                    echothiophate iodide increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • fesoterodine

                    fesoterodine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • finerenone

                    oxybutynin topical will increase the level or effect of finerenone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed.

                  • flavoxate

                    flavoxate and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • fluphenazine

                    oxybutynin topical decreases levels of fluphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of fluphenazine by pharmacodynamic antagonism. Use Caution/Monitor.

                    fluphenazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • galantamine

                    galantamine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • glycopyrrolate

                    glycopyrrolate and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • glycopyrrolate inhaled

                    glycopyrrolate inhaled and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • haloperidol

                    oxybutynin topical decreases effects of haloperidol by pharmacodynamic antagonism. Use Caution/Monitor.

                    oxybutynin topical decreases levels of haloperidol by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    haloperidol increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • henbane

                    henbane and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • homatropine

                    homatropine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • huperzine A

                    huperzine A increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • hyoscyamine

                    hyoscyamine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • hyoscyamine spray

                    hyoscyamine spray and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • iloperidone

                    oxybutynin topical decreases levels of iloperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of iloperidone by pharmacodynamic antagonism. Use Caution/Monitor.

                    iloperidone increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • imipramine

                    oxybutynin topical and imipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • ipratropium

                    ipratropium and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor. Due to the poor systemic absorption of ipratropium, interaction unlikely at regularly recommended dosages.

                  • isavuconazonium sulfate

                    oxybutynin topical will increase the level or effect of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

                  • ivacaftor

                    oxybutynin topical increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors .

                  • lofepramine

                    oxybutynin topical and lofepramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • lomitapide

                    oxybutynin topical increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day.

                  • loxapine

                    oxybutynin topical decreases levels of loxapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of loxapine by pharmacodynamic antagonism. Use Caution/Monitor.

                    loxapine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • loxapine inhaled

                    loxapine inhaled increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                    oxybutynin topical decreases levels of loxapine inhaled by pharmacodynamic antagonism. Use Caution/Monitor.

                  • maprotiline

                    oxybutynin topical and maprotiline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • meclizine

                    meclizine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • methscopolamine

                    methscopolamine and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • metoclopramide

                    oxybutynin topical decreases effects of metoclopramide by pharmacodynamic antagonism. Use Caution/Monitor. May antagonize prokinetic effects.

                  • neostigmine

                    neostigmine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • nitrofurantoin

                    oxybutynin topical increases levels of nitrofurantoin by unspecified interaction mechanism. Use Caution/Monitor.

                  • nortriptyline

                    oxybutynin topical and nortriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • olanzapine

                    oxybutynin topical decreases levels of olanzapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of olanzapine by pharmacodynamic antagonism. Use Caution/Monitor.

                    olanzapine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • onabotulinumtoxinA

                    onabotulinumtoxinA and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • orphenadrine

                    oxybutynin topical and orphenadrine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • oxybutynin

                    oxybutynin and oxybutynin topical both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • paliperidone

                    oxybutynin topical decreases levels of paliperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of paliperidone by pharmacodynamic antagonism. Use Caution/Monitor.

                    paliperidone increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • pancuronium

                    oxybutynin topical and pancuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • perphenazine

                    oxybutynin topical decreases levels of perphenazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of perphenazine by pharmacodynamic antagonism. Use Caution/Monitor.

                    perphenazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • physostigmine

                    physostigmine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • pilocarpine

                    pilocarpine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • pimozide

                    oxybutynin topical decreases levels of pimozide by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of pimozide by pharmacodynamic antagonism. Use Caution/Monitor.

                    pimozide increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • pralidoxime

                    oxybutynin topical and pralidoxime both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • prochlorperazine

                    oxybutynin topical decreases levels of prochlorperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of prochlorperazine by pharmacodynamic antagonism. Use Caution/Monitor.

                    prochlorperazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • promethazine

                    oxybutynin topical decreases levels of promethazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of promethazine by pharmacodynamic antagonism. Use Caution/Monitor.

                    promethazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • propantheline

                    oxybutynin topical and propantheline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • protriptyline

                    oxybutynin topical and protriptyline both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • pyridostigmine

                    pyridostigmine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • quetiapine

                    oxybutynin topical decreases levels of quetiapine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of quetiapine by pharmacodynamic antagonism. Use Caution/Monitor.

                    quetiapine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • rapacuronium

                    oxybutynin topical and rapacuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • risperidone

                    oxybutynin topical decreases levels of risperidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of risperidone by pharmacodynamic antagonism. Use Caution/Monitor.

                    risperidone increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • rocuronium

                    oxybutynin topical and rocuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • scopolamine

                    oxybutynin topical and scopolamine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • solifenacin

                    oxybutynin topical and solifenacin both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • succinylcholine

                    succinylcholine increases and oxybutynin topical decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.

                  • thioridazine

                    oxybutynin topical decreases levels of thioridazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of thioridazine by pharmacodynamic antagonism. Use Caution/Monitor.

                    thioridazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • thiothixene

                    oxybutynin topical decreases levels of thiothixene by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of thiothixene by pharmacodynamic antagonism. Use Caution/Monitor.

                    thiothixene increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • tinidazole

                    oxybutynin topical will increase the level or effect of tinidazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.

                  • tiotropium

                    oxybutynin topical and tiotropium both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • tolterodine

                    oxybutynin topical and tolterodine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • trazodone

                    oxybutynin topical and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • trifluoperazine

                    oxybutynin topical decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.

                    trifluoperazine increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • trihexyphenidyl

                    oxybutynin topical and trihexyphenidyl both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.

                  • trimipramine

                    oxybutynin topical and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • trospium chloride

                    oxybutynin topical and trospium chloride both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • vecuronium

                    oxybutynin topical and vecuronium both decrease cholinergic effects/transmission. Use Caution/Monitor.

                  • ziprasidone

                    oxybutynin topical decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor.

                    ziprasidone increases effects of oxybutynin topical by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.

                  • zotepine

                    oxybutynin topical decreases levels of zotepine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.

                    oxybutynin topical decreases levels of zotepine by pharmacodynamic antagonism. Use Caution/Monitor.

                  Minor (20)

                  • acetaminophen

                    oxybutynin topical decreases levels of acetaminophen by unspecified interaction mechanism. Minor/Significance Unknown.

                  • acetaminophen IV

                    oxybutynin topical decreases levels of acetaminophen IV by unspecified interaction mechanism. Minor/Significance Unknown.

                  • acetaminophen rectal

                    oxybutynin topical decreases levels of acetaminophen rectal by unspecified interaction mechanism. Minor/Significance Unknown.

                  • amantadine

                    amantadine increases effects of oxybutynin topical by pharmacodynamic synergism. Minor/Significance Unknown.

                  • atenolol

                    atenolol increases levels of oxybutynin topical by decreasing metabolism. Minor/Significance Unknown.

                  • chlorpromazine

                    oxybutynin topical increases toxicity of chlorpromazine by unspecified interaction mechanism. Minor/Significance Unknown.

                  • digoxin

                    oxybutynin topical increases levels of digoxin by unspecified interaction mechanism. Minor/Significance Unknown.

                  • dimenhydrinate

                    dimenhydrinate increases toxicity of oxybutynin topical by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.

                  • donepezil

                    donepezil decreases effects of oxybutynin topical by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • fluphenazine

                    oxybutynin topical increases toxicity of fluphenazine by unspecified interaction mechanism. Minor/Significance Unknown.

                  • galantamine

                    galantamine decreases effects of oxybutynin topical by pharmacodynamic antagonism. Minor/Significance Unknown.

                  • levodopa

                    oxybutynin topical, levodopa. Other (see comment). Minor/Significance Unknown. Comment: Anticholinergic agents may enhance the therapeutic effects of levodopa; however, anticholinergic agents can exacerbate tardive dyskinesia. In high dosage, anticholinergics may decrease the effects of levodopa by delaying its GI absorption. .

                  • perphenazine

                    oxybutynin topical increases toxicity of perphenazine by unspecified interaction mechanism. Minor/Significance Unknown.

                  • prochlorperazine

                    oxybutynin topical increases toxicity of prochlorperazine by unspecified interaction mechanism. Minor/Significance Unknown.

                  • promazine

                    oxybutynin topical increases toxicity of promazine by unspecified interaction mechanism. Minor/Significance Unknown.

                  • promethazine

                    oxybutynin topical increases toxicity of promethazine by unspecified interaction mechanism. Minor/Significance Unknown.

                  • ruxolitinib

                    oxybutynin topical will increase the level or effect of ruxolitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

                  • ruxolitinib topical

                    oxybutynin topical will increase the level or effect of ruxolitinib topical by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.

                  • thioridazine

                    oxybutynin topical increases toxicity of thioridazine by unspecified interaction mechanism. Minor/Significance Unknown.

                  • trifluoperazine

                    oxybutynin topical increases toxicity of trifluoperazine by unspecified interaction mechanism. Minor/Significance Unknown.

                  Previous
                  Next:

                  Adverse Effects

                  NOTE: anticholinergic adverse effects are less with topical application compared with oral administration

                  1-10%

                  Xerostomia (7.5%)

                  Urinary tract infection (6.9%)

                  Application site reaction (5.4%)

                  Dizziness (2.8%)

                  Fatigue (2.1%)

                  Constipation (1.3%)

                  Previous
                  Next:

                  Warnings

                  Contraindications

                  Hypersensitivity

                  Gastric retention

                  Uncontrolled narrow-angle glaucoma

                  Urinary retention

                  Conditions that severely decrease GI motility

                  Cautions

                  Caution with clinically significant bladder outflow obstruction because of the risk of urinary retention

                  Caution with gastrointestinal obstructive disorders or decreased intestinal motility because of the risk of gastric retention

                  Caution with GERD and/or those taking drugs that can cause or exacerbate esophagitis (eg, bisphosphonates)

                  Caution with myasthenia gravis because of decreased cholinergic activity

                  Discontinue if skin hypersensitivity occurs

                  Caution with other anticholinergics (antimuscarinics); may increase risk for xerostomia, constipation, headache, dizziness, somnolence, and blurred vision

                  Angioedema requiring hospitalization and emergency medical treatment has occurred with the first or subsequent doses of oral oxybutynin; in the event of angioedema, oxybutynin containing products should be discontinued and appropriate therapy promptly provided

                  Somnolence reported with oxybutynin-containing products; use caution with activities requiring mental alertness

                  Gelnique is flammable

                  Previous
                  Next:

                  Pregnancy & Lactation

                  Pregnancy Category: B

                  Lactation: Unknown whether distributed in breast milk, caution advised

                  Pregnancy Categories

                  A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

                  B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

                  C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

                  D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

                  X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

                  NA: Information not available.

                  Previous
                  Next:

                  Pharmacology

                  Mechanism of Action

                  Exerts antispasmodic and antimuscarinic effects on smooth muscle; decreases uninhibited urinary contractions, and delays desire to void; increases bladder capacity

                  Pharmacokinetics

                  Vd: 193 L (IV)

                  Peak Plasma Concentration: 6.8-8.3 ng/mL (gel)

                  Metabolism: bypasses first-pass in liver by CYP3A4, AUC ratio of N-desethyloxybutynin (active metabolite) to parent compound is 1:1

                  Previous
                  Next:

                  Images

                  No images available for this drug.
                  Previous
                  Next:

                  Patient Handout

                  A Patient Handout is not currently available for this monograph.
                  Previous
                  Next:

                  Formulary

                  FormularyPatient Discounts

                  Adding plans allows you to compare formulary status to other drugs in the same class.

                  To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

                  Create Your List of Plans

                  Adding plans allows you to:

                  • View the formulary and any restrictions for each plan.
                  • Manage and view all your plans together – even plans in different states.
                  • Compare formulary status to other drugs in the same class.
                  • Access your plan list on any device – mobile or desktop.

                  The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

                  View explanations for tiers and restrictions
                  Tier Description
                  1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
                  2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
                  3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
                  4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
                  NC NOT COVERED – Drugs that are not covered by the plan.
                  Code Definition
                  PA Prior Authorization
                  Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
                  QL Quantity Limits
                  Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
                  ST Step Therapy
                  Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
                  OR Other Restrictions
                  Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
                  CLOSE
                  Additional Offers
                  CLOSE
                  Email to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  CLOSE
                  Email Forms to Patient

                  From:

                  To:

                  The recipient will receive more details and instructions to access this offer.

                  By clicking send, you acknowledge that you have permission to email the recipient with this information.

                  Previous
                  Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.
                  Find Us On
                  About
                  About Medscape Privacy Policy Editorial Policy Cookies Terms of Use Advertising Policy Help Center
                  Membership
                  Become a Member About You Professional Information Newsletters & Alerts
                  App
                  Medscape
                  WebMD Network
                  Medscape Live Events WebMD MedicineNet eMedicineHealth RxList WebMD Corporate
                  Editions
                  English Deutsch Español Français Português
                  All material on this website is protected by copyright, Copyright © 1994-2022 by WebMD LLC. This website also contains material copyrighted by 3rd parties.